Atomo Diagnostics : ASX Small and Mid-Cap Conference Presentation

Atomo Diagnostics Limited

Authorised by John Kelly, Managing Director

Level 1, 3-5 George Street,

Leichhardt, NSW 2040

Australia

use only

ASX Presentation

ersonal

March 2022

ATOMOATOMODIAGNOSTICSDIAGNOSTICSLIMITEDLIMITED| (ASX:| (ASX:AT1)AT1)

DISCLAIMER

This presentation has been prepared by Atomo Diagnostics Limited ("Atomo") based on information available as at the date of this presentation. The information in this onlypresentation is provided in summary form and does not contain all information necessary to make an investment decision. Reliance should not be placed on the information or opinions contained in this presentation. An investor must not act on the basis of any matter contained in this presentation but should make its own assessment

of Atomo as part of its own investigations.

This presentation has been provided for general information purposes only. It does not constitute an offer, invitation, solicitation or recommendation with respect to the usepurchase or sale of any security in Atomo, nor does it constitute financial product advice or take into account any individual's investment objectives, taxation situation,

financial situation or needs.

Although reasonable care has been taken to ensure that the facts stated in this presentation are accurate and that the opinions expressed are fair and reasonable, no representation or warranty, express or implied, is made as to the fairness, accuracy,

completeness or correctness of the information, opinions and conclusions contained in ersonalthis presentation. To the maximum extent permitted by law, neither Atomo, nor any of its officers, directors, employees and agents, nor any other person, accepts any

responsibility or liability for the content of this presentation including, without limitation, any liability arising from fault or negligence, for any loss arising from the use of or reliance on any of the information contained in this presentation or otherwise arising in connection with it. This disclaimer also extends to all and any information and opinions contained in, and any omissions from, any other written or oral

ATOMO DIAGNOSTICS LIMITED | (ASX: AT1)

communications transmitted or otherwise made available to the recipient in connection with the opportunity outlined in this presentation and no representation or warranty is made in respect of such information.

The information presented in this presentation is subject to change without notice and Atomo does not have any responsibility or obligation to inform you of any matter arising or coming to their notice, after the date of this presentation, which may affect any matter referred to in this presentation. The cover image is illustrative only.

This presentation may contain certain forward looking statements that are based on Atomo's beliefs, assumptions and expectations and on information currently available to Atomo management. Such forward looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results or performance of Atomo to be materially different from the results or performance expressed or implied by such forward looking statements. Such forward looking statements are based on numerous assumptions regarding present and future business strategies and the business, economic and competitive environment in which they operate in the future, which are subject to change without notice. Past performance is not necessarily a guide to future performance and no representation or warranty is made as to the likelihood of achievement or reasonableness of any forward looking statements or other forecast. To the full extent permitted by law, Atomo and its directors, officers, employees, advisers, agents and intermediaries disclaim any obligation or undertaking to release any updates or revisions to information to reflect any change in any of the information contained in this presentation (including, but not limited to, any assumptions or expectations set out in the presentation).

2

INTRODUCTION

	Atomo Diagnostics Limited (ASX: AT1) is an innovative medical
only	device diagnostics company supplying unique, integrated rapid
diagnostic test (RDT) devices and finished point-of-care rapid
tests to the global market
	Headquartered in Australia with international operations, Atomo
	develops, manufactures and sells innovative patented devices
use	and innovative rapid tests that address unmet user needs
Increasing market traction locally in Australia as well as
	established business in the US, Europe and Global Health
	markets selling approved Atomo finished tests to healthcare
ersonal	distributors and Atomo devices to diagnostic partners (OEM)
Atomo has experienced strong growth since FY19, with $7m
	in H1 FY22 revenues from customers, exceeding FY21
	revenues of $6.7m
	Cash on hand at 31/1/22 of $15.8m, no debt
	ATOMO DIAGNOSTICS LIMITED | (ASX: AT1)

3

TRANSFORMING THE SELF TESTING EXPERIENCE

ersonal use only

FROM Traditional 'bits in a box' LFA kits

Issues with standard rapid test kits

Low user satisfaction and regulatory challenges

Complex (multiple components, too many steps and complex workflow)

High error rates (10% by healthcare professional, 30%+ by untrained self-test users)

ATOMO DIAGNOSTICS LIMITED | (ASX: AT1)

TO Atomo's user-friendlyall-in-one solution

Advantages of Atomo devices INNOVATIVE: One fully-patenteddevice, >90% of users prefer

ACCURATE: Easy to use, always the right amount of blood and reagent seamlessly delivered to the test strip

RELIABLE: Less than 1% error rates (< 3% first time untrained users)

4

ATOMO'S CORE CAPABILITIES

The intersection between Medical Devices & Diagnostics

use only

IP Intensive

Atomo DNA

Point-of-Care Self Testing

• Design and engineering
• Patent generation
• Prototype and test
• Co-development
• Regulatory processes
• User centric design

Core Functionality		Devices
•	Blood collection	•	Galileo
•	Saliva & swab collection	•	Pascal
•	Buffer delivery	•	Elion
•	Interlocks	•	Da Vinci
•	Manufacturing machinery	•	Non-Blood devices
•	and processes		for Swab and Saliva
IFU's
•	Digital, App

Less IP Intensive

More sales focused

Finished Products	Customer Delivery
•	HIV	•	Atomo Direct to
•	COVID	•	consumer
•		Subscription models
Others *	•	White label brand
•	HCV		partnerships in eHealth
•	HIV / Syphilis		channels
•	Anemia /

Coeliac / Vit. D

* Products under consideration in Pipeline

ersonal

Atomo has commercialised rapid blood test devices with a level of integrated functionally and user simplicity unmatched in the rapid test market The company is now actively focused on commercialising integrated devices that materially improve testing with swab and saliva samples

ATOMO DIAGNOSTICS LIMITED | (ASX: AT1)

5